Ranloc Med, 20 mg, 14 enteric-resistant tablets

Ranloc Med, indications:

Drug intended for short-term treatment of symptoms of gastroesophageal reflux disease (such as heartburn, acid regurgitation) in adults.

Composition:

Each gastro-resistant tablet contains 20 mg of pantoprazole (as 22.6 mg of pantoprazole sodium sesquihydrate).

The other ingredients are:

• Tablet core: anhydrous sodium carbonate, mannitol (E 421), crospovidone type A, hydroxypropylcellulose, microcrystalline cellulose, calcium stearate.
• Tablet coating: hypromellose, propylene glycol, povidone K30, titanium dioxide (E 171), yellow iron oxide (E 172).
• Enteric coating: methacrylic acid and ethyl acrylate copolymer (1 :1), triethyl citrate, sodium lauryl sulfate, titanium dioxide (E 171), talc, yellow iron oxide (E 172).
• Printing ink: shellac, black iron oxide (E 172), propylene glycol .

Contraindications:

• Hypersensitivity to the active substance or to any of the excipients.
• Simultaneous administration with Atazanavir.

Recommended use:

Ranloc Med always should be used as described in the package leaflet or as directed by your doctor or pharmacist. Before first use, consult your doctor.

The recommended dose is 20 mg pantoprazole (one tablet) daily. The tablet should be taken before a meal, swallowed whole with water.

You may need to take the tablets for another 2 to 3 days to get relief from your symptoms. Once symptoms have completely disappeared, treatment should be discontinued. Without consulting a doctor, treatment should not last longer than 4 weeks.

If symptoms do not subside within 2 weeks of continuous treatment, contact your doctor.

Additional information:

Before use, read the leaflet, which contains indications, contraindications, data on side effects, dosage and information on the use of the medicinal product, or consult a doctor or pharmacist, because any medicine used incorrectly poses a threat to your life or health.